Nuclear Receptor Cofactor Detection Method for High-Throughput Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional methods for screening drug candidates targeting nuclear receptors are inefficient due to their inability to rapidly and conveniently assess the physiological effects of substances on these receptors, requiring complex cell cultures and lengthy processes, and are not suitable for high-throughput screening of numerous samples.
Innovation Solution
A detection method involving a nuclear receptor-cofactor system where a nuclear receptor protein is exposed to a surface with bound cofactors, allowing for the detection of substances binding to the receptor based on changes in binding affinity, using recombinant proteins and a microwell plate format for efficient screening.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If a receptor binding assay is used to screen drug candidates, then the degree of binding can be determined rapidly, but the physiological effects (agonistic or antagonistic) of the chemical substance cannot be determined
Solution Approach 1:
The patent combines the rapid binding detection capability of receptor binding assays with the physiological effect detection capability of cofactor interaction assays into a single integrated system. By simultaneously measuring both receptor binding and cofactor recruitment, the method determines both binding affinity and physiological effect (agonistic or antagonistic) in one experiment, resolving the contradiction between screening speed and information completeness.
Solution Approach 2:
The patent introduces a labeled cofactor as an intermediary element that mediates between the nuclear receptor and the detection system. The cofactor serves as a bridge that translates the physiological state of the receptor-ligand complex into a measurable signal, enabling detection of agonistic or antagonistic effects without sacrificing screening efficiency.
2Loss of information
If cell-based assays (reporter gene assay or two-hybrid assay) are used to determine physiological effects, then agonistic or antagonistic effects can be detected, but the assay process becomes complex and time-consuming due to cell culturing requirements
Solution Approach 1:
The patent extracts the essential functional elements (nuclear receptor and cofactor interaction) from the complex cell-based assay system and performs the detection in a simplified in vitro environment. By removing the cellular machinery and focusing only on the critical protein-protein interaction between receptor and cofactor, the method maintains physiological effect detection capability while eliminating the complexity of cell culturing and manipulation.
Solution Approach 2:
The patent uses recombinant proteins expressed in simple systems (such as bacteria) as disposable substitutes for complex living cells. These recombinant proteins perform the specific function of interest (receptor-cofactor interaction) without requiring the full complexity of living cell systems, enabling rapid and simple assays that can be easily prepared and discarded.
3Loss of information
If cell-based assays are used to determine physiological effects, then agonistic or antagonistic effects can be detected, but the assay requires a long period of time due to cell growth being the rate-determining step
Solution Approach 1:
The patent performs preliminary preparation of recombinant nuclear receptor and cofactor proteins in advance using simple expression systems. These pre-prepared proteins are then ready for immediate use in the functional assay, eliminating the time-consuming cell growth phase. The rate-determining step is shifted from cell proliferation to protein preparation, which can be done more efficiently and in parallel.
4Measurement precision
If conventional ELISA-based cofactor-containing receptor-ligand assay systems are established for each receptor-cofactor combination, then specific detection can be achieved, but a large number of assay systems are required which is not efficient
Solution Approach 1:
The patent develops a universal assay platform that can detect multiple different nuclear receptor-cofactor combinations using a single standardized protocol. By using a common detection approach (measuring cofactor recruitment to receptor) that applies to all nuclear receptors, the method eliminates the need to develop separate ELISA-based assay systems for each combination, reducing the number of systems from many to one while maintaining detection specificity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides high sensitivity and convenience in detecting agonists, antagonists, or modulators of nuclear receptors, enabling rapid and efficient establishment of a detection system capable of handling multiple nuclear receptor-cofactor combinations, thus facilitating drug discovery.
Implementation Method 1
detecting a substance which is contained in the test sample and which binds to the nuclear receptor, on the basis of a change in degree of binding between the nuclear receptor protein and the cofactor
Data Source
AI summary
Provided is a detection method including exposing, to contact with a surface to which a cofactor has been bound, a nuclear receptor protein serving as a counterpart of the cofactor and a test sample; and detecting a substance which is contained in the test sample and which binds to the nuclear receptor, on the basis of a change in degree of binding between the nuclear receptor protein and the cofactor. The detection method is means for detecting a living-body-related substance, which means employs a nuclear receptor-cofactor system, exhibits detection high sensitivity, provides a convenient detection process, and realizes efficient establishment of a detection system.